29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC)
Gandara D, Hua X, Tolba K, Fabrizio D, Albacker L, Brennick R, Montesion M, Oxnard G, Adam S, Hirsch F, Kelly K, Herbst R, LeBlanc M, Redman M, Wu M, Kozono D. 29 Lung-MAP composite signature for immune checkpoint inhibitor (ICI) efficacy in advanced squamous cell lung cancer (SCC). 2022, a31-a31. DOI: 10.1136/jitc-2022-sitc2022.0029.Peer-Reviewed Original ResearchSquamous cell lung cancerAdvanced squamous cell lung cancerImmune checkpoint inhibitor efficacyCheckpoint inhibitor efficacyCell lung cancerLung cancerInhibitor efficacyCancer